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ABSTRACT 
Abeysekera, Irushi S. M.S., Purdue University, August 2014. Effect of Epigallocatechin-
3-gallate on Skeletal and Cognitive Phenotypes in a Down syndrome Mouse Model. 
Major Professor: Randall J Roper. 
 
 
 
Down Syndrome (DS), a genetic disorder that affects ~1 in 700 live births, is caused by 
trisomy of human chromosome 21 (Hsa21). Individuals with DS are affected by a wide 
spectrum of phenotypes which vary in severity and penetrance. However, cognitive and 
skeletal impairments can be commonly observed in all individuals with DS. To study 
these phenotypes, we utilized the Ts65Dn mouse model that carries three copies of 
approximately half the gene orthologs found on Hsa21 and exhibit similar phenotypes as 
observed in humans with DS. Individuals with DS and Ts65Dn mice have deficits in 
bone mineral density (BMD), bone architecture, bone strength, learning and memory. 
Over-expression of DYRK1A, a serine-threonine kinase encoded on Hsa21, has been 
linked to deficiencies in DS bone homeostasis and cognition. Epigallocatechin-3-gallate 
(EGCG), an aromatic polyphenol found in high concentrations in green tea, is a selective 
inhibitor of DYRK1A activity. Normalization of DYRK1A activity by EGCG therefore 
may have the potential to ameliorate skeletal and cognitive deficits. We hypothesized that 
supplements containing EGCG obtained from health food stores/ online vendors will not 
be as effective as EGCG from a chemical company in correcting bone deficits associated 
 
xii 
 
 
with DS. Our results suggest that EGCG improves the bone mineral density of trisomic 
femurs significantly better than the supplements while the EGCgNOW supplement from 
NOW FOODS improves trabecular and cortical bone structure. The results from HPLC 
analysis of supplements showed the presence of other catechins in EGCgNOW and 
degradation analysis revealed the rapid degradation of supplements. Therefore we 
hypothesize that the presence of EGCG degradation products and other green tea 
catechins in supplements may play a role in the differential skeletal effects we observed.  
We further hypothesized that a three week treatment of adolescent mice with EGCG will 
lead to an improvement in the learning and memory deficits that are observed in trisomic 
animals in comparison to control mice. However, our results indicate that three weeks of 
low-dose EGCG treatment during adolescence is insufficient to improve hippocampal 
dependent learning and memory deficits of Ts65Dn mice. The possibility remains that a 
higher dose of EGCG that begins at three weeks but lasts throughout the behavioral test 
period may result in improvement in learning and memory deficit of Ts65Dn mice.  
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CHAPTER 1. INTRODUCTION 
1.1 Down syndrome 
Down syndrome (DS) is the most common genetic cause of mental retardation 
and results from the triplication of human chromosome 21 (Hsa21) (LEJEUNE 1959). In 
most instances DS results from the non-disjunction of the Hsa21 during meiosis as a 
freely segregating chromosome or as a Robertsonian translocation (EPSTEIN 2001a). The 
rarest form of DS is mosaicism, a condition caused by the presence of trisomic cells 
together with normal diploid cells. Mosaic phenotypes and severity depend upon the 
number and distribution of trisomic cells within organs with individuals with lower 
number of trisomic cells being asymptomatic (EPSTEIN 2001a). The only apparent risk 
factor associated with DS is maternal age and this becomes clear when studying the rates 
of non-disjunction during gamete formation. Non-disjunction occurs 86% of the time 
during female oocyte formation with predominate errors (75%) occurring during meiosis 
I (EPSTEIN 2001a). There are 552 genes on Hsa21 of which 161 genes are RefSeq protein 
coding sequences (STURGEON and GARDINER 2011).  
DS has an incidence rate of approximately 1 in 700 live births and results in a 
constellation of phenotypes that affect the cardiovascular, central nervous, and skeletal 
systems among others (SPENCER 2001; RICHTSMEIER et al. 2002; VAN CLEVE SN 2006a; 
VAN CLEVE SN 2006b; CLEVES et al. 2007). Some of the commonly occurring 
phenotypes are hearing loss (75%), vision loss (60%), obstructive sleep apnea (50-75%), 
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congenital heart disease (40-60%), refractive errors (50%), infections of the middle ear 
(50-70%), hypodontia and delayed tooth eruptions (23%), low IQ and an Alzheimer 
disease like phenotype when individuals are 50-60 years of age (MARILYN J. BULL ; 
ROUBERTOUX and KERDELHUE 2006; NETZER et al. 2010; BULL and GENETICS 2011).  
There exists however wide variability in phenotypic incidence and severity in individuals 
with DS (EPSTEIN 2001a; ROUBERTOUX and KERDELHUE 2006).  
 
1.1.1 History of Down syndrome 
The first book on mental disorders was published in 1838 by Jean-Etienne-
Dominique Esquirol where he identified a collection of phenotypes that we now know as 
Down syndrome (DS). Esquirol in “Des maladies mentales considérées sous les rapports 
medical, hygiénique et medico-légal” describes a group of patients with physical 
attributes that ranged from a flat nasal bridge, protruding tongue, oblique eye fissures, 
short stocky stature, malformed neck and epicanthic eye folds to mental retardation 
(ESQUIROL 1845). In 1846 Edouard Séguin added to the observations of Esquirol and 
described characteristics of a small nose, open mouth, tongue morphology and an 
increase in susceptibility to infections. He also stated that the affected children were mild 
natured and had the ability to gain language skills and coined the term “furfuraceous 
cretinism” to describe them (SEGUIN 1866). In 1866, John Langdon Down noted in 
London Hospital Reports a group of individuals with characteristics similar to those 
observed in individuals from Mongolia and he coined the term “Mongols” to describe 
them. He described them to have a flat broad face with straight and scanty hair, round 
cheeks, narrow palpebral fissures, a small nose and a long thick tongue. He further 
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described them as being great mimics with a lively sense of humor and speech that is 
thick and indistinctive (DOWN 1866). He observed that training improved speech, 
coordination, physical and mental abilities, and that they possessed on average much 
reduced life expectancies (ROUBERTOUX and KERDELHUE 2006). The term “mongolism” 
was used to describe these individuals until the mid-nineteenth century. In 1961 the 
Lancet published a letter penned by a group of 19 scientists who suggested that the term 
“mongolism” should be discarded as it is “an embarrassing term” and “has no scientific 
basis” and it should be replaced by a more suitable term. They suggested the use of 
“Langdon-Down’s anomaly” “Down’s syndrome or anomaly”, “congenital acromicria”, 
or “trisomy 21 anomaly” (HOWARD-JONES 1979). The term “mongolism” was officially 
removed from use by the World Health Organization (WHO) in 1965 following a request 
by the Mongolian delegation (HOWARD-JONES 1979). In 1975, the United States Institute 
of Health (NIH) convened a conference during which it was suggested that the possessive 
term “Down’s syndrome” be replaced by “Down syndrome” (1975).  
The genetic cause of DS was not described till the mid-19th century during which 
time a number of other discoveries that facilitated the identification of the genetic basis of 
DS were made. In the early part of the 19th century, Thomas H. Morgan and colleagues 
published a manuscript that presented evidence to support the theory that genes are 
contained on the chromosome (PATTERSON and COSTA 2005). Joe H. Tjio and Albert 
Levan used sample spreads of metaphase chromosome cell cultures of fetal lung tissue to  
positively identify that humans had  46 chromosomes (TJIO and LEVAN 1956). The 
chromosomal basis of DS was discovered in May 1958 by the French pediatrician and 
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geneticist Jerome Lejeune who observed an extra copy of the human 21st chromosome 
(Hsa21) in human fibroblast tissue samples (LEJEUNE 1959).  
 
1.1.2 Genotype- phenotype relationship 
The development of therapeutic interventions for individuals with DS relies 
greatly upon understanding the genotype-phenotype correlation, the role of Hsa21 gene(s) 
and their interactions with non-Hsa21 genes in the development of various DS 
phenotypes. There are several methods in which the genotype-phenotype relationship can 
be studied, including (1) mapping of partial human trisomies (2) use of segmentally 
trisomic mouse models,  (3) studying gene expression in cells and tissues isolated from 
individuals with DS and mouse models, and (4) triplication of a single trisomic gene in a 
mouse model (transgenic mouse models) (ALTAFAJ et al. 2001; LYLE et al. 2009).  The 
discovery of the chromosomal basis of DS by Lejeune in 1959 subsequently lead to the 
study of the chromosomal structure to pinpoint the exact region of Hsa21 responsible for 
the myriad phenotypes observed in individuals with DS. The study of individuals with 
partial trisomy lead to the identification of the distal region of Hsa21, in particular the 
region of 21q22 as responsible for causing many of the DS phenotypes including mental 
retardation (MCCORMICK et al. 1989). The “Down syndrome critical or chromosomal 
region” (DSCR) was described to extend for 5.4 Mb on Hsa21 from a proximal boundary 
between markers D21S17 and D21S55 to distal boundary between MX1 and BCEI and 
carry 33 genes (DELABAR et al. 1993; KORENBERG et al. 1994). The general consensus at 
this time was that genes located on the DSCR alone were responsible for causing most of 
the major phenotypes observed in individuals with DS (KORENBERG et al. 1990). 
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However, experiments conducted in mice that were trisomic for the DSCR (Ts1Rhr) 
disproved this theory by showing that the genes on the DSCR alone are not sufficient for 
the generation of the craniofacial phenotype and mental retardation (OLSON et al. 2004a). 
The analysis of  DNA from individuals with partial trisomy 21 yielded results showing 
that some regions on Hsa21 may play a major role in specific phenotypes (KORBEL et al. 
2009; LYLE et al. 2009).  The genomic regions of eight phenotypes associated with DS in 
30 individuals with partial trisomy 21 were mapped using DNA which was first 
karyotyped and then analyzed using multicolor fluorescence in situ hybridization (FISH) 
and array maps (KORBEL et al. 2009). The DS-specific congenital heart disease (DSCHD) 
was one of the phenotypes that Korbel et al. studied as it is a major phenotype observed 
in individuals with DS. DSCHD is associated with abnormal development of the 
atrioventricular septal defects (AVSD) and an individual with DS has a risk ~1000 fold 
greater than the general population of developing DSCHD (KORBEL et al. 2009).  Korbel 
et al. identified a 2.82 Mb region on Hsa21 from DNA obtained from 14 individuals 
previously diagnosed with DSCHD that were critically associated with the development 
of endocardial cushion defects which lead to valve and septal defects (KORBEL et al. 
2009). Further analysis using the mouse model Dp(16)1Yu/+ narrowed the DSCHD 
critical region down to a 1.77 Mb section with 10 genes of which only the Down 
syndrome cell adhesion molecule (DSCAM) gene was highly expressed in the developing 
heart and therefore was noted as the likely candidate gene for DSCHD (KORBEL et al. 
2009). Hirschsprung disease (HSCR) is a congenital gut disease where DS individuals 
have a 100 fold greater risk than the general population (TORFS and CHRISTIANSON 1998). 
In the same study the DSCAM gene was also implicated as a candidate gene for HSCR, 
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supporting the results observed in a previous study (YAMAKAWA et al. 1998). Individuals 
with DS have an increased risk of developing Alzheimer disease (AD) and APP, a Hsa21 
gene has been shown to play a critical role in disease development (ROVELET-LECRUX et 
al. 2006). The region of Hsa21 involved in AD phenotype was narrowed down to a 1.95 
Mb region which included APP (KORBEL et al. 2009). Another study published in 2009 
identified 25 phenotypes that were associated with DS in 19 individuals with partial 
trisomy and 27 phenotypes in 11 monosomy individuals (LYLE et al. 2009).  
The two studies published by Korbel and Lyle provided key pieces of evidence in the 
quest for understanding the correlation between genotype-phenotype and provided 
evidence to further dispel the DSCR theory by showing that different regions on Hsa21 
are responsible for the generation of different phenotypes.  
 
1.1.3 Skeletal phenotype in individuals with DS 
As average life expectancy of individuals with DS increases due to advances in 
healthcare, so does the likelihood of the development of age-related diseases like 
osteoporosis, diabetes, and autoimmune disorders (VAN ALLEN et al. 1999; MCKELVEY et 
al. 2012). Osteoporosis is defined as “a disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and the 
consequent increase in fracture risk” (KANIS et al. 1994). Individuals with DS possess a 
number of features which make them more susceptible to the development of an 
osteoporosis like phenotype. They generally suffer from thyroid abnormalities, hypotonia, 
and reduced physical activity levels (GUIJARRO et al. 2008). It was therefore suggested 
that the distal portion of Hsa21 may play a role in the development of osteoporosis in DS 
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(TUMER et al. 2005). Guijarro and his colleagues studied the effect of trisomy 21 on bone 
mineral density (BMD) in individuals (age 19-45 years) with DS who did not suffer from 
any comorbidity that may influence BMD levels (GUIJARRO et al. 2008).  They identified 
that the areal BMD was significantly lower in the spine, femoral neck, total hip, and total 
body in individuals with DS in comparison to the control group (GUIJARRO et al. 2008). 
Another study conducted by Baptista et al. found that the volumetric BMD in lumbar 
spine and the femoral neck strength were significantly altered in DS individuals 
(BAPTISTA et al. 2005). A significantly lower level of bone formation serum markers 
(P1NP) with no accompanying significant change to reabsorption markers were observed 
in biochemical analysis of blood from young adult DS individuals (MCKELVEY et al. 
2012). Bone formation and reabsorption mainly occur during childhood and adolescence 
in a process known as bone turnover where osteoblasts and osteoclasts work together to 
create and lengthen the skeleton while the same cells help maintain the skeleton 
throughout adulthood (MCKELVEY et al. 2012). McKelvey and colleagues in their study 
found that individuals with DS have a significantly decreased bone turnover and they 
concluded that it is the combination of altered bone formation and reabsorption that is the 
primary cause of low bone mass that is observed in individuals with DS (MCKELVEY et 
al. 2012).  
 
1.1.4 Cognitive phenotype in individuals with DS 
DS is the leading genetic cause of mental retardation and results in mild to severe 
learning and memory deficits (GARDINER et al. 2003; ROUBERTOUX and KERDELHUE 
2006). Mental retardation  in DS is characterized by impairments in hippocampal 
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dependent memory functions, reduced size of hippocampus and cerebellum, reduced 
dendritic and axonal number and volume, early occurrence of Alzheimer disease, motor 
dysfunction and altered synaptic plasticity (BECKER et al. 1991; MARTINEZ DE LAGRAN et 
al. 2004; COPPUS et al. 2006; LORENZI and REEVES 2006; GUIDI et al. 2008). Alterations 
in brain morphology are apparent in newborns with the amygdala, cerebellum, brain stem, 
and prefrontal cortex undergoing a reduction in volume (DIERSSEN 2012). The dendrites 
play a key role in synaptic transmission, and in infants and children with DS a reduction 
in dendritic spines along with atrophy of the dendritic tree can be observed (TAKASHIMA 
et al. 1989). Within the first few months of life, developmental delays (motor and 
cognitive) can be observed in infants with the delays becoming more and more 
significant over time; another noticeable alteration is the decline in intelligent quotient 
(IQ) which follows a downward trend from infanthood (<1 year) to adolescence (>11 
years) (EPSTEIN 2001a). Behavioral problems such as obsessive/compulsive behaviors, 
low attention span, and stubbornness are a common occurrence in children with DS (4-18 
years) which can hamper their personal and social development (CLARK and WILSON 
2003). Adults (20-50 years) show a more varied neurological profile with motor function 
and coordination of movements, language, verbal short-term memory (short term 
retention of words) and declarative long-term memory (conscious recollection of 
memories of facts and events) more severely impaired than other forms of memory 
(LATASH and ANSON 2006; DIERSSEN et al. 2009). Furthermore, the structure of the 
dendrites continue to deteriorate in adults leading to reductions in dendritic branching, 
length and spine numbers (TAKASHIMA et al. 1989).  
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1.2 Mouse models of DS 
The complex disease pathology of DS resulted in the generation of mouse models 
to study the genotype-phenotype relationship, the role of a chromosomal region or 
specific genes on the pathogenesis of DS, and possible therapeutic interventions. Mouse 
models of DS are based upon the orthologous nature between Hsa21 and mouse 
chromosome 16, 17, and 10 (Mmu16, 17, 10) (Fig. 1.1) (PLETCHER et al. 2001; 
STURGEON and GARDINER 2011). Mouse models can be divided in to three types based 
upon the method of creation, 1- segmentally trisomic mouse models: Ts65Dn, Ts1Rhr, 
Ts1Cje, Ts1Yah, p(10)1Yey/+, Dp(16)1Yey/+, Dp(17)1Yey/+, 2- transchromosomic 
mouse model (Tc1, Dp(10)1Yey/+; Dp(16)1Yey/+;Dp(17)1Yey/+), 3- transgenic mouse 
models (TgDyrk1a).  
The Ts(1716)65Dn (hereafter referred as Ts65Dn) mouse model is the most 
extensively studied and widely used animal model of DS and captures most of the 
behavioral defects that are seen in humans with DS (DAVISSON et al. 1993; LIU et al. 
2011). Ts65Dn mice carry a genomic fragment of 13 Mb that extends from Mrpl39 to the 
telomere of Mmu16 and trisomic for approximately half the gene orthologous found on 
Hsa21 (DAVISSON et al. 1993; REEVES et al. 1995; HATTORI et al. 2001). Ts65Dn mice 
replicate many of the DS phenotypes including abnormal dendritic spine density and 
structure, altered hippocampal functions, severe reduction in LTP, and skeletal 
abnormalities (BELICHENKO et al. 2004; KLESCHEVNIKOV et al. 2004; BELICHENKO et al. 
2007; BELICHENKO et al. 2009b; BLAZEK 2011). The Ts1Cje mouse model, generated by 
Charles J. Epstein’s laboratory by gene targeting, carries a ~ 8.1 Mb genomic fragment 
that is of Mmu16 in origin and orthologous for approximately 67% of the Hsa21 genes 
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that are triplicated in Ts65Dn mice (SAGO et al. 2000; OLSON et al. 2004b). These mice 
display abnormalities in dendritic structure, function, and number with altered synaptic 
plasticity (BELICHENKO et al. 2007). The Ts1Rhr mouse model was generated in the 
laboratory of Roger Reeves and carries an extra segment of the Mmu16 region from 
Cbr1-Fam3b (~ 33 genes) thus making it an excellent model to study the importance of 
the DSCR (DELABAR et al. 1993; OLSON et al. 2004a). The Ts1Rhr mice display learning 
and memory deficits and abnormalities in dendritic spine morphology and number with 
accompanying alteration of long term potentiation (LTP), an essential factor of synaptic 
plasticity (BELICHENKO et al. 2009a). The Ts1Yeh mouse model was created recently in 
Yann Herault’s laboratory in France and carries a small Hsa21 homologous 0.59 Mb 
duplicated region of Mmu17 (PEREIRA et al. 2009). The Ts1Yeh mice differ from other 
mouse models whereby the duplicated region has resulted in the increase of LTP within 
the hippocampus and thus providing some evidence to the relationship between the three 
mouse chromosomal regions in phenotype development (PEREIRA et al. 2009). The 
Dp(10)1Yey/+, Dp(16)1Yey/+,and  Dp(17)1Yey/+ mouse models were created in the 
laboratory of Eugene Yu and carry duplicated regions of each Hsa21 homologous regions 
on Mmu10, 16, and 17 respectively (YU et al. 2010a). The Dp(10)1Yey/+ mice showed 
no impairments in LTP or in behavioral tests while Dp(16)1Yey/+ mice displayed 
decreased LTP and cognitive deficits and the Dp(17)1Yey/+ mice had increased 
hippocampal LTP (YU et al. 2010b).  
The first complete transchromosomal mouse model, Tc1 was created by Elizabeth 
Fisher in 2005 and carries a freely segregating copy of Hsa21 resulting in the triplication 
of 200 RefSeq genes (O'DOHERTY et al. 2005; GRIBBLE et al. 2013). The Tc1 mice were 
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shown to have impairment in short term memory with long term memory and synaptic 
plasticity been preserved (MORICE et al. 2008). These mice performed poorly in Morris 
water maze (MWM) and novel object learning and memory tasks and displayed 
reductions in LTP (O'DOHERTY et al. 2005; MORICE et al. 2008). However one of the 
major drawbacks of this mouse model is that the freely segregatingHsa21 within the 
mouse genome results in a high degree of mosicism within tissues (SALEHI et al. 2007). 
Recently the laboratory of Eugene Yu created another transchromosomal mouse model 
that is trisomic to all Hsa21 homologous regions (YU et al. 2010a). The 
Dp(10)1Yey/+;Dp(16)1Yey/+;Dp(17)1Yey/+ mouse model was created by normal 
breeding to generate compound mutant mice carrying two different duplications and then 
used these compound mutants to cross with the mutant carrying the third duplication to 
generate mice carrying all three Mmu regions (YU et al. 2010a). The mutant mice had a 
significantly higher latency, slower swimming speed and a longer path length to the 
hidden platform in the MWM task during training and on the probe day the mutant mice 
spent a significantly lower amount of time in the target quadrant than control animals 
(YU et al. 2010a). The mutant mice also displayed impairment in grip strength and a 
significant reduction in hippocampal LTP. 
Transgenic mouse models allow the users to study the effect of a specific gene of 
phenotype development. Transgenic mice overexpressing Dyrk1A (TgDyrk1A) were 
created to specially study the role of Dyrk1A, a candidate gene for learning and memory 
deficits in DS (ALTAFAJ et al. 2001). These mice showed impairments in cognitive 
function but had an increased hippocampal LTP (AHN et al. 2006). 
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1.2.1 Skeletal phenotype of Ts65Dn mice 
The Ts65Dn mouse model is an excellent predictive animal model of skeletal 
abnormalities that are observed in individuals with DS. In a previous study conducted in 
our lab, we identified that bone development and homeostasis was altered in trisomic 
mice at both 6 and 16 weeks of age (BLAZEK 2011).  Blazek and colleagues analyzed 
femurs and skulls of 6 and 16 week trisomic and euploid mice using dual energy x-ray 
absorptiometry (DXA), micro CT, histomorphometry, and 3-point bend test. The bone 
mineral density (BMD), bone mineral content (BMC), percent bone volume (BV/TV) and 
trabecular number showed significant reductions in trisomic femurs at 6 and 16 weeks 
while trabecular separation was significantly increased. The trabecular thickness was 
lower in Ts65Dn mice but this reduction was found to be non-significant at the time 
points observed. The mid-shaft of the femurs are made up of cortical bone and analysis of 
this section by micro CT revealed that at 6 and 16 weeks the trisomic mice exhibit a 
significant reduction in mean total cross-sectional area, mean polar moment of inertia, 
and mean total periosteal perimeter. The mineralization rate of femurs in trisomic and 
euploid mice was observed by injecting them with two labels (calcein green and alizarin 
red) four days apart prior to death. Both trisomic and euploid mice had similar number of 
active osteoblasts in the femur but at 6 weeks, trisomic mice had a significantly lower 
mineral apposition rate on the periosteal surface of femur in comparison to age matched 
euploid littermates. The bone formation rate in the femurs was also shown to be 
significantly reduced in trisomic mice in comparison to controls. In the final part of the 
study, the strength of the femurs was analyzed via 3-point bending to study the effect of 
all of the above changes on the structure of the bones. Ts65Dn mice had a significantly 
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lower ultimate load and stiffness at 6 and 16 weeks than euploid controls while the 
energy to failure was reduced but the change was non-significant in 16 week old femurs. 
All of the results gathered by Blazek et al., clearly showed that trisomic mice were 
affected by a significantly altered skeletal phenotype which was present from 
adolescence to adulthood (BLAZEK 2011). In a 2012 study Fowler et al. studied the 
skeletal phenotype of Ts65Dn mice at 3 and 24 months of age (FOWLER et al. 2012). 
They observed the structural morphology of the proximal tibia and distal femur of 3 and 
24 month old trisomic mice and euploid mice and observed that the trabecular bone 
underwent significant changes that include reduction of percent bone volume (BV/TV), 
and trabecular number along with an increase in trabecular separation (FOWLER et al. 
2012). The cortical bone that makes up the mid-shaft of the femur was found to have a 
significant reduction in cortical thickness at both time points while in the older mice the 
periosteal cross section, cortical cross-sectional area, and total cross sectional area also 
underwent a significant reduction. The significant reductions to the cortical bone in 24 
month old mice were also associated with a reduction in mechanical strength. Static 
histomorphometric analysis of the proximal tibia and distal femurs of 3 month old mice 
further supported the above observations by showing that a significant reduction in the 
number of osteoblasts and osteoclasts on the bone surface along with reductions in bone 
formation and reabsorption markers with an overall reduction in bone turnover was 
present at this time point (FOWLER et al. 2012). The results observed by Fowler et al., 
verified the results observed in our lab and showed that the skeletal phenotype that is 
present during adolescence persists through adulthood. 
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1.2.2 Behavioral phenotype of Ts65Dn mice 
The Ts65Dn mouse model has been used extensively to explore the deficits in 
brain structure and function in DS (ESCORIHUELA et al. 1995; REEVES et al. 1995; 
BELICHENKO et al. 2004; KLESCHEVNIKOV et al. 2004; BELICHENKO et al. 2007; 
BELICHENKO et al. 2009b). The alterations observed in Ts65Dn mice include spontaneous 
locomotor hyperactivity, impaired performance in MWM and novel object recognition 
tasks, reduced dendrite density and enlarged spine heads, and severe impairment of 
hippocampal LTP (BELICHENKO et al. 2007; BELICHENKO et al. 2009b). Learning and 
memory functions are most commonly studied in the hippocampus, a structure tightly 
linked with cognitive functions (NADEL and BOHBOT 2001). Behavioral tasks have been 
utilized to study the many deficits that Ts65Dn mice possess due to trisomy. Tasks such 
as the MWM, novel object recognition (NOR), delayed non-matching to place (DNMP), 
and locomotor activity are commonly used to study the hippocampus dependent learning 
and memory deficits (MIZUMORI et al. 1999; D'HOOGE and DE DEYN 2001; FERNANDEZ 
et al. 2007). The MWM, developed by RG Morris is used to study spatial learning of a 
task and the ability to remember said task following a delay (MORRIS et al. 1982). The 
MWM task is used very often in assessment of hippocampal dependent learning and 
memory functions in Ts65Dn mice (SAGO et al. 2000; HYDE et al. 2001). Ts65Dn mice 
have been shown to have significant deficits in the MWM task with an increased latency 
(time taken to reach the platform)  and poorer spatial navigational performance compared 
to euploid controls (ESCORIHUELA et al. 1995; REEVES et al. 1995; SAGO et al. 2000; 
HYDE et al. 2001). The NOR task is based upon the natural tendency of rodents to 
explore novel objects and environments (CLARK et al. 2000; SQUIRE et al. 2007) . It has 
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been reported in previous studies that Ts65Dn mice were less able to discriminate 
between a novel and a familiar object and displayed deficits in episodic memory 
functions (FERNANDEZ et al. 2007). The DNMP (T-maze) task is based upon the natural 
tendency of mice to alternate goal arms and is based upon “working memory”, where the 
decision made the “choice” trial of a trial couplet is based upon what was learned in the 
“forced” trial (OLTON 1979; DEMBER 1989). Ts65Dn mice showed a severe deficit in 
working memory in the T-maze with a significantly lower percentage of spontaneous 
alternation in the maze in comparison to control mice (KLESCHEVNIKOV et al. 2012). 
Several studies have reported that the spontaneous locomotor activity of Ts65Dn mice is 
significantly increased leading to a higher level of hyperactivity than observed in control 
mice (HOLTZMAN et al. 1996; SAGO et al. 2000; KLESCHEVNIKOV et al. 2012).  The 
performances of Ts65Dn mice in these hippocampus dependent behavioral tasks points 
towards the presence of major deficits in this region of the brain.  
 
1.3 DYRK1A/Dyrk1a 
DYRK1A (dual specificity tyrosine-regulated kinase 1A) is a member of the 
highly regulated DYRK protein kinase family (TEJEDOR and HAMMERLE 2011). The 
DYRK1A gene is located on Hsa21 and is found in three copies in individuals with DS. 
Ts65Dn mice have three copies of the Dyrk1a gene which is found on Mmu16. It 
functions as a master regulator of important processes such as the development of the 
central nervous system (CNS), cell death, synaptic plasticity, and osteoclastogenesis (LEE 
et al. 2009b; TEJEDOR and HAMMERLE 2011). DYRK1A is highly expressed in fetal and 
adult brains during the development, neurogenesis and differentiation indicating that it 
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has an important role in the functioning of the CNS (DELABAR et al. 1993; GUIMERA et al. 
1999). The extra copy of DYRK1A in humans with DS (older than 3 years) has been 
shown to lead to a 1.5 fold increase in protein levels in brain tissues which is 
hypothesized to cause cognitive deficits (DOWJAT et al. 2007). The dosage imbalance of 
Dyrk1a is hypothesized to result in the development of a number of phenotypes observed 
in DS and in mouse models of DS including behavioral and skeletal deficits (KORENBERG 
et al. 1994; ARRON et al. 2006). The NFATc1 (Nuclear factor of Activated T-cells 1) 
pathway is a critical regulator of development in vertebrates and plays a crucial role in 
bone development and neurogenesis (RICHTSMEIER et al. 2000; ARRON et al. 2006). It is 
referred to as a “master” transcription factor for osteoclastogenesis as its induction is 
essential for cell fate determination (ASAGIRI and TAKAYANAGI 2007). The mechanism of 
action of NFATc is induced when calcium (Ca2+) enters into the cell which leads to the 
activation of calcineurin, which dephosphorylates cellular NFATc protein facilitating its 
nuclear entry and subsequent gene transcription (Figure 1.2). In DS, it is hypothesized 
that overexpression of DYRK1A leads to a significant increase in the phosphorylation of 
NFATc1, reducing its nuclear presence and preventing it from functioning as a 
transcription factor (ARRON et al. 2006; GWACK et al. 2006). The validity of this 
mechanism has been shown in Nfatc-null mice, where knocking out Nfatc resulted in 
alterations to the craniofacial, cerebellar granule cell population and muscle development 
(ARRON et al. 2006). Another important gene involved in the NFAT pathways is RCAN 
(DSCR1) that codes for an inhibitor of the calcineurin/NFAT signaling pathway, the 
triplication of which in Ts65Dn mice resulted in an increased inhibition of the pathway  
(ARRON et al. 2006). 
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The generation of transgenic Dyrk1a mice by deleting one copy of the gene 
(Dyrk1a+/-) resulted in developmental delays, neuronal deficits and overall reductions in 
CNS development. The deletion of both copies of the gene (Dyrk1a-/-) resulted in 
gestational death, indicating that Dyrk1a is a key factor during development (FOTAKI et 
al. 2002). A transgenic mouse model overexpressing Dyrk1a protein was used to test the 
hypothesis that overexpression of Dyrk1a alone is sufficient to develop motor and 
cognitive deficits, and the results from this study showed the  important role Dyrk1a 
plays during development (ALTAFAJ et al. 2001).  
 
1.4 Treatment options 
The current accepted protocol for treatment of cognitive and skeletal deficits in 
individuals with DS is early intervention to aid in learning and social interactions and 
treatment of symptoms and parathyroid hormone (PTH) treatment. However, as the life 
expectancy of individuals with DS and our knowledge of the genotype-phenotype 
association have increased in the past decade or so, so has the need to develop 
pharmaceutical interventions to help ameliorate the cognitive, skeletal and other 
phenotypes. Here we focus on treatment options that target various aspects of the 
cognitive and skeletal deficit. All individuals with DS suffer from some form of mental 
retardation and therefore there are many different methods of intervention being studied 
in laboratories all over the world. These include pharmacological targeting of 
neurotransmitters, environmental enrichment, DYRK1A inhibition and normalization of 
gene dosage, oxidative stress reduction, and normalization of excitatory/inhibitory 
balance. Hippocampal dysfunction is believed to be one of the most important factors that 
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give rise to reduced cognitive function in individuals with DS and in the Ts65Dn mouse 
model (HYDE et al. 2001; PENNINGTON et al. 2003). Ts65Dn mice have significantly 
reduced adult neurogenesis in the dentate gyrus of hippocampal formation (CLARK et al. 
2006).  Therapeutic agents that can therefore enhance development of the hippocampus 
are being investigated for their validity in mouse models. Ts65Dn mice (neonate and 2-5 
month old) when injected with fluoxetine, a serotonin (5-HT) reuptake inhibitor, showed 
a significant increase in adult neurogenesis in the hippocampus which in some cases were 
accompanied by improvements in behavioral deficits (CLARK et al. 2006; BIANCHI et al. 
2010). Synaptic plasticity relies on the excitatory/inhibitory balance of the synapses and 
in Ts65Dn mice there is reduced excitatory synapses which leads to enhanced inhibition 
(KURT et al. 2000; FERNANDEZ et al. 2007). Ts65Dn mice (3-4 months of age) injected 
intraperitoneally with Picrotoxin (PTX), a GABAA   antagonist performed significantly 
better than untreated mice in an object recognition task and normalized long term 
potentiation (LTP) (FERNANDEZ et al. 2007). Increased oxidative stress may also 
contribute to impaired neurogenesis, and treatment of Ts65Dn mice with vitamin E, an 
antioxidant, has been shown to reduce markers of oxidative stress (GARDINER 2010). 
Another interesting avenue of treatment is maternal choline supplementation and in 
Ts65Dn mice, supplementation of the mothers diet with extra choline lead to a significant 
improvement in performance of adult mice in the radial arm water maze, a hippocampal 
dependent task and in adult neurogenesis (VELAZQUEZ et al. 2013). In a study conducted 
by Fowler et al. intermittent treatment of 3 month old Ts65Dn mice with parathyroid 
hormone (PTH) was shown to result in a significant increase in whole body BMD, bone 
formation rate, BV/TV, trabecular number and thickness. The results from this study 
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provided significant evidence to the use of PTH (FDA approved for bone anabolic 
therapy) in ameliorating the altered skeletal phenotype in DS (FOWLER et al. 2012). 
A recent study concluded in Spain, studied the validity of Epigallocatechin-3-
gallate (EGCG) in improving the learning and memory function in individuals with DS 
and in Ts65Dn mice (DE LA TORRE et al. 2014). In this study the participants were orally 
administrated an EGCG supplement dose of 9mg/kg/day then subjected to  various 
neurophysiological tests, biochemical analyses and a self-made interview with parents to 
understand the effect of the treatment. The results revealed that EGCG treatment lead to 
improvements in episodic and working memory and in social interactions and parents 
when interviewed reported many positive changes in behavior (DE LA TORRE et al. 2014). 
 
1.4.1 Epigallocatechin-3-gallate (EGCG) 
Green tea is a popular beverage prepared by drying fresh tender tea leaves (YANG 
and LANDAU 2000). Polyphenols account for approximately 30-40% of the solid tea 
leaves of which epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin-
3-gallate (ECG) and epicatechin (EC) are the most common (Figure 1.3)(SATO and 
MIYATA 2000). Green tea consists primarily of EGCG (50%) followed by ECG and EGC 
(KHOKHAR et al. 1997). EGCG is a small molecule that has many therapeutic effects such 
as anti-cancer activity, anti-oxidant activity, anti-bacterial activity, anti-allergic activity 
and anti-inflammatory activities (LIN and LIN 1997; BROWN 1999; YANG and LANDAU 
2000; MAEDA-YAMAMOTO et al. 2004; KO et al. 2009). EGCG is a selective inhibitor of 
DYRK1A activity and is thought to function by binding to the ATP binding domain of 
the protein and inhibiting its activity (BAIN et al. 2003; ADAYEV et al. 2006). Green tea 
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catechins undergo rapid degradation following treatment leading to poor bioavailability 
(FERRUZZI et al. 2010). The degradation leads to oxidation, dimerization, and 
polymerization of catechins leading to the formation of hydrogen perioxide free radicals 
in aqueous media. The rate of degradation of EGCG in aqueous solution is dependent 
upon pH, incubation time, and temperature (NAKAYAMA et al. 2002). The bioavailability 
of EGCG was shown to be increased in the presence of ascorbic acid which reduces the 
solution pH (FERRUZZI et al. 2010). Previous studies in which the cognitive phenotype of 
TgDyrk1a and Ts65Dn mice was studied following oral administration of EGCG have 
shown that the treatment rescues learning and memory deficits, increases brain volume 
and rescues synaptic plasticity deficits (GUEDJ et al. 2009; DE LA TORRE et al. 2014).  In 
another study, treatment with EGCG was shown to inhibit β-Amyloid peptide formation 
which leads to Alzheimer disease (AD) and lead to an improvement in memory function 
in a mouse model of AD (LEE et al. 2009a).  
 
1.5 Thesis Hypothesis 
HYPOTHESIS 1: Effect of different EGCG supplements on correcting skeletal deficits in 
a Down syndrome mouse model. 
We hypothesized that EGCG supplements obtained from different vendors (online and 
health food stores) will have a differential effect in ameliorating the skeletal phenotype in 
Ts65Dn mice with chemical grade EGCG from Sigma resulting in the greatest 
improvement.  
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HYPOTHESIS 2: Study the effect of a three week EGCG treatment on the learning and 
memory defects in the Ts65Dn mouse model of Down syndrome.  
We hypothesized that a three week treatment of sigma EGCG would result in 
improvements in cognitive function in trisomic mice when tested on locomotor activity, 
novel object recognition, T maze, and Morris water maze tasks in comparison to euploid 
control mice. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Effect of different EGCG supplements on correcting skeletal deficits in a Down 
syndrome mouse model 
 
2.1.1 Ts65Dn husbandry 
Female B6EiC3Sn a/A-Ts(1716)65Dn (Ts65Dn), C57BL/6J (B6) and 
C3H/HeJ(C3H) mice were purchased from the Jackson Laboratory (Bar Harbor, MI). The 
B6C3F1 mice were bred by crossing B6 and C3H males and females. Ts65Dn females 
(approximately 50% B6 and 50% C3H background with small trisomic marker 
chromosome) were bred to B6C3F1 males to generate the mice used in the study. Pups 
were born following 19-21 days of gestation. On postnatal day 6-10 (PD6-10) tissue was 
obtained and DNA isolated for genotyping by PCR. Only male mice were used in this 
study due to the sub fertile nature of the Ts65Dn males and the importance of females in 
colony maintenance. Pups were weaned on PD21, and male mice were single housed and 
randomly assigned to the different treatment groups 
 
2.1.2 Mouse genotyping by PCR 
All mice born into the colony were genotyped using the breakpoint PCR 
(REINHOLDT et al. 2011). The breakpoint PCR makes use of a Chr17fwd primer 
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(GTGGCAAGAGACTCAAATTCAAC) and Chr16rev primer 
(TGGCTTATTATTATCAGGGCATTT) set to amplify a ~275 bp product at the 
translocation point on 1716 murine chromosome and a positive control primer set of 
IMR1781 (TGTCTGAAGGGCAATGACTG) and IMR1782 
(GCTGATCCGTGGCATCTATT) that amplifies a 544bp product. The final PCR mix 
contained 10X reaction buffer, dNTPs, MgCl2, Taq polymerase, water, two sets of 
primers, and DNA. The PCR cycling conditions were set to 94°C for 2 minutes to 
initialize the reaction followed immediately by 45 seconds at 94°C to melt the template 
DNA in a denaturation step that yields single stranded DNA molecules. The template 
DNA was then cooled down to 55°C for 45 seconds to allow annealing of the primers to 
the template, and strand elongation to occur through the action of Taq polymerase at 
72°C for 1 minute. The denaturation, annealing and elongation steps were repeated for 34 
cycles and were followed by a final elongation step for 7 minutes at 72°C. To verify the 
PCR products, the samples were separated on a 1.5% agarose gel made by dissolving 
0.75 g of agarose in 50 mL 1X TAE buffer. The size(s) of PCR products were determined 
by comparison with a DNA ladder, which contained DNA fragments of known size, run 
alongside the products on the gel. This is a crucial step in our studies as it is important to 
positively distinguish trisomic Ts65Dn mice from the euploid mice. The repeated 
backcrossing of the Ts65Dn females to C3H/HeJ males would lead to approximately 25% 
of all Ts65Dn pups born with this background to be homozygous for the C3H-derived 
retinal degeneration mutation Pde6brd1  that causes blindness within the first few weeks of 
life (COSTA et al. 2010). Therefore, all mice born in to the colony were screened for 
retinal degeneration (Rd) (JACKSON 2007). The PCR mix contained 10X KCl reaction 
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buffer, MgCl2, dNTPs, primers- IMR2093 (AAgCTAgCTgCAgTAACgCCATTT- 560 
bp), IMR2094 (ACCTgCATgTgAACCCAgTATTCTATC- 240 bp), IMR2095 
(CTACAgCCCCTCTCCAAggTTTATAg- 560 and 240 bp), water and Taq polymerase 
enzyme. The Rd PCR utilized three separate primers to identify the mice that are 
heterozygous (rd/+), mutated (rd/rd) or wild type (+/+). The reaction was initialized by 
holding the samples at 94°C for 5 minutes immediately followed by 30 seconds at 94°C 
to melt the template DNA in to single strands of DNA.  The template DNA was then 
cooled down to 65°C for 30 seconds to facilitate the attachment of primers to the 
template, and strand elongation was performed through the action of Taq polymerase at 
72°C for 1.5 minute. The denaturation, annealing and elongation steps were repeated for 
35 cycles and were followed by a final elongation step for 2 minutes at 72°C. The PCR 
products were held at 10°C until they were separated on a 1.5% agarose gel. Only 
heterozygous (rd/+) and wild type (+/+) male mice were utilized in this study. 
 
2.1.3 HPLC analysis of EGCG supplements 
EGCG supplements from the following 8 sources were chosen for analysis: 
EGCG (Sigma Aldrich, St. Louis MO), EGCG (Swanson Health Products, Fargo ND), 
EGCgNOW (NOW Foods, Bloomingdale IL), EGCG (Source Naturals, Scotts Valley 
CA), TEAVIGO (Healthy Origins, Pittsburgh PA), Green tea extract 50% EGCG 
(hardrhino.com), Fluka, and SAFC. An Agilent 1200SL High Performance Liquid 
Chromatography (HPLC) instrument was used and coupled with an Agilent 6520 
quadrupole time-of-flight mass spectrometer (MS). Samples were separated using reverse 
phase chromatography with a Zorbax Eclipse XD8-C18 (4.6 mm x 150 mm, and 5 µM 
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particle size). The mobile phase employed a HPLC gradient elution. Solvent A was 
ammonium acetate and solvent B was acetonitrile with 0.1% methanol, and ammonium 
acetate. A stepwise gradient was started with 10% B, increased to 40% B after 5 minutes, 
100% from 5.50 minutes to 8 minutes, and then decreased to 10% after 2 minutes. Ultra-
violet light was used to quantify and identify EGCG at a wavelength of 254 nm.   
 
2.1.4 Degradation analysis of EGCG supplements by HPLC-MS 
The potent antioxidant nature of EGCG leads to the rapid degradation of catechins 
under room temperature conditions, leading to poor bioavailability (FERRUZZI et al. 2010). 
Therefore in addition to purity testing, EGCG, TEAVIGO, EGCgNOW and 2 other 
compounds (Life Extension decaffeinated mega green tea extract and Life Extension 
lightly caffeinated mega green tea extract) used in a recently published study (DE LA 
TORRE et al. 2014) were analyzed for their rate of degradation.  Stock solutions of 10 
mg/mL of EGCG were prepared by dissolving the substances in phosphate buffered 
saline (PBS). All stock solutions utilized in the degradation analysis were refrigerated to 
maintain their stability. The supplements EGCG, TEAVIGO, EGCgNOW, Life 
Extension decaffeinated mega green tea extract (DE EGCG), and Life Extension lightly 
caffeinated mega green tea extract (LE EGCG) were diluted to a final concentration of 1 
mg/mL in tap water and kept under room conditions to correspond to our general 
treatment protocols. The sample dilutions were prepared in triplicates to be tested 1, 24, 
and 48 hours following their preparation. Due to degradation within an aqueous solution, 
a set of EGCG samples stabilized to a pH between 5.00 and 5.55 with phosphoric acid 
(H3PO4) were also analyzed (FERRUZZI et al.). All HPLC/MS analyses were performed 
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in collaboration with Drs. Karl Dria and Tax Georgiades of the Department of Chemistry 
and Chemical Biology at IUPUI.  
Samples were analyzed using an Agilent 1200SL HPLC instrument coupled with 
an Agilent 6520 quadrupole time-of-flight mass spectrometer (MS). Samples were 
separated using reverse phase chromatography with a Zorbax Eclipse Plus C18 column 
(2.1 mm diameter, 50 mm length, 1.8 micron particle size) operating at a temperature of 
40°C. Solvents of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic 
acid (B) were used with a stepwise gradient starting with 10% B and ending with 95% B 
over 5 minutes. Ultra-violet absorption was used to quantify the organic EGCG 
compound at a wavelength of 230 nm. Calibration curves were prepared using EGCG 
with concentrations ranging from 0.1-1 mg/mL. MS using electrospray negative 
ionization operating in Auto-MS mode was used to determine the exact mass and 
possible formula assignments of the compounds and their fragment. Results were 
analyzed using MassHunter qualitative (mass analysis and formula assignments) and 
quantitative (UV quantitation) analysis software packages.  
 
2.1.5 EGCG treatment preparation 
Following HPLC analysis EGCG and two supplements TEAVIGO and 
EGCgNOW were chosen to treat Ts65Dn and euploid mice to study the effect of EGCG 
on the skeletal phenotype following HPLC analysis. TEAVIGO supplement by Healthy 
Origins (Pittsburgh, PA) contained 90% by weight EGCG per capsule and is sold as a 
metabolism enhancer while EGCgNOW (Bloomingdale, IL) possessed an EGCG content 
of 50% by weight per capsule and was marketed as a dietary supplement that provides 
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antioxidant and cellular health support (Table 2.1). Stock solutions of 10X TEAVIGO 
and EGCgNOW were prepared by dissolving a capsule in 103 and 161 mL of tap water, 
respectively. The solutions were briefly (5-10 minutes) placed in a 37°C water bath to 
ensure that they dissolved completely. The stock solutions were refrigerated at 4°C and 
diluted as needed. Working solutions of 20-25 mL of 0.124 mg/mL were prepared in tap 
water and were placed in the drinking tubes every other day.  
Trisomic and euploid mice were randomly assigned to treatment groups at 
PD21and given free access to EGCgNOW, TEAVIGO or water (Eu, water n=18, 
TEAVIGO n=13, EGCgNOW n=10 and Ts, water n=10, TEAVIGO n=10, EGCgNOW 
n=10). On PD43 the mice were killed using cervical dislocation following prolonged 
exposure to isoflurane, USP (Piramal Healthcare, Andhra Pradesh, India). The femurs, 
mandibles, and skulls were immediately extracted and stored at -20° C until further 
analyses. All animal use and protocols were approved by the School of Science IACUC 
committee at IUPUI. 
 
2.1.6 Dual energy X-ray absorptiometry (DXA) 
The bone mineral density (BMD) and bone mineral content (BMC) of the femurs 
and skulls was analyzed using the Lunar Piximus DXA machine (PIXImus Lunar Corp., 
Madison, WI). The machine was calibrated prior to each use. The femurs and entire 
skulls were placed caudal side down on the densitometer and scanned using ultrahigh 
resolution (0.18 mm × 0.18 mm) (LI et al. 2009). Lunar Piximus 2 2.0 software was used 
to assess BMD, bone mineral content (BMC), and total bone area. 
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2.1.7 Micro CT imaging and analysis 
Femurs were imaged using the SkyScan 1172 micro CT (SkyScan, Kontich, 
Belgium). The femurs from trisomic and control mice were thawed at room temperature 
and wrapped in parafilm, placed in a Styrofoam mold fitted to the rotating stage in the 
machine. The scanning parameters were set as follows: voltage 60 kV, resolution 6 μm, 
binning mode 2 k, and filter Al 0.5 mm. A reconstruction and analysis was conducted on 
each set of images using CTrecon and CTan software from Skyscan with the following 
parameters: post alignment variable, smoothing 2, ring artifact reduction 5, beam 
hardening 20, and threshold 0–0.11. A region of interest was created consisting of the 
boundaries of trabecular bone in the distal femur and 1 mm of tissue, proximal to the 
growth plate was analyzed. 3D analysis was conducted on the trabecular bones to obtain 
percent bone volume, trabecular number, thickness, and separation measurements. The 
cortical bone analysis of the mid-shaft of the femur was performed by a 2D analysis on a 
single section to obtain the total and bone areas, periosteal perimeter, and mean polar 
moment of inertia (MPMI) (calculated from CTan). The anterior–posterior diameter and 
average cortical thickness of a femur mid-shaft cross-section was measured using CTan 
and the cross-sectional moment of inertia was calculated from these measures. 
 
2.1.8 Mechanical testing 
The strength of the femur was determined by 3-point bending using a miniature 
materials machine (100 R250 Modular Test System, TestResources Inc, Shakopee, MN) 
(TURNER and BURR 1993). The femurs were thawed to room temperature, and placed 
posterior side down on the lower supports of the 3-point bending apparatus held apart at 7 
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mm. The femur was placed so that the force was applied to the midpoint of the bone at all 
times. The femur was preloaded using 0.1 N to establish contact with the bone and the 
displacement rate was set at 0.1 mm/s. Once preloaded, force was applied gradually until 
the bone was broken. Data were gathered by the program and analyzed using Microsoft 
Excel. The ultimate force (maximum force sustained by the bone, Figure 4), energy to 
failure (area under load-deformation curve before bone is broken, Figure 5), and stiffness 
of the bone (slope of the linear portion of load-deformation curve, Figure 6) were 
determined using a load-deformation curve as previously defined (MASHIBA et al. 2000).   
 
2.1.9 Statistical Analysis 
Data were analyzed using a standard two-tailed t-test with significance considered 
as p-values less than or equal to 0.05. 
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2.2 Study of the effect of a three week EGCG treatment on the learning and memory 
defects in the Ts65Dn mouse model of Down syndrome 
 
2.2.1 EGCG preparation and treatment 
EGCG obtained from Sigma Aldrich (EGCG, <95%) was chosen as the standard 
treatment due to its high level of purity. A stock solution of 15 mg/mL was made by 
dissolving 30 mg of solid EGCG in 2 mL of PBS and was refrigerated to maintain 
stability. Treatments of 0.124 mg/mL concentration were prepared by diluting the stock 
solution in tap water. Treatments carried out in the initial part of the study (cohorts 1- 10, 
Ts= 23, Eu=33) were done using EGCG that was not pH balanced. In the latter part of the 
study (cohorts 11-13, Ts=12, Eu=5), the EGCG and water (control) treatments were pH 
balanced using phosphoric acid (pH 5-5.5).  
Male mice at PD21 were weaned and randomly assigned to 4 treatment groups 
that received either EGCG or water, (Ts, EGCG n=17, water n=15 and Eu, EGCG n=12, 
water n=14). Treatments were placed in drinking tubes and changed every 48 hours. All 
treatments were changed over to water after three weeks (PD49) and the animals were 
subjected to a series of behavioral tasks to assess their cognitive abilities.  
 
2.2.2 Locomotor activity 
Several groups have previously reported that Ts65Dn mice show a significant 
increase in hyperactivity in spontaneous locomotor activity tasks when compared to 
euploid controls (REEVES et al. 1995; HOLTZMAN et al. 1996; SAGO et al. 2000). Ts65Dn 
and control mice were placed in an activity chamber (Med Associates Inc., St. Albans, 
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VT) with Plexiglas long walls and aluminum side walls, with each chamber (25.0 × 13.75 
× 15.0 cm) equipped with infrared beams along the length of the chamber 2.5 cm above 
the floor. The chambers were housed in light- and sound-attenuated wooden cubicles 
with ventilation fans on one side of the cubicle.  Testing was conducted in the dark 
during the dark phase of the animals for 30 minutes on two consecutive days. Following 
the conclusion of the test on each day, the mice were returned to their home cages and the 
chambers were thoroughly cleaned with 70% ethanol.  
 
2.2.3 Novel object recognition (NOR) 
Rodents have a natural preference towards novel objects than objects they have 
been previously exposed to and the NOR task can be utilized to study the long term 
object recognition in trisomic mice in comparison to controls (FERNANDEZ et al. 2007; 
SMITH et al. 2014). NOR task was performed following previously described protocols 
with modifications (BABOVIC et al. 2008; O'TUATHAIGH et al. 2010). The task was 
conducted over three days during the dark cycle under red light as described below. 
 
1. Habituation day (day 1) - Subject was placed inside the test arena for 15 minutes and 
allowed to familiarize itself with the environment. Activity was measured using 
ANY-maze video tracking systems (Stoelting Co, Wood dale, IL). At the end of the 
15 minutes, the subject was returned to the home cage and the test arena was cleaned 
with 70% ethanol between each animal.  
2. Exposure day (day 2) –Two similar objects were attached at the NW and SE corners 
of the arena, 5 cm from both walls to facilitate exploration around each object. Each 
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test mouse was placed at the midpoint of the wall opposite to the sample objects; with 
their nose facing the wall away from objects and allowed to explore the arena for 15 
minutes.  Time spent interacting with each object was determined as nose or whiskers 
touching the object or directed toward it within <1cm, or touching the object with a 
paw. Accidental contact with object (i.e., bumping or using the object as a platform to 
explore the arena) was not counted as interaction with the object.  
3. Test day (day 3) – One object from exposure day and a novel object was assigned to 
each corner randomly. The animal was placed as described above and given 15 
minutes to explore the objects and activity was tracked using ANYMAZE software 
and returned to the home cage at the end of the experiment.  
 
Video recordings from the exposure and test days were scored for the time spent 
exploring each object by a minimum of three independent observers who were blind to 
experimental conditions to ensure accuracy. The data gathered from the videos were used 
to determine the discrimination ratio using the following formula: 
Discrimination ratio (%) = Time exploring novel object- Time exploring familiar object * 
100 
 
2.2.4 Delayed non-matching to place (DNMP) task 
The DNMP task is based upon the natural tendency of rodents to spontaneously 
alternate between left and right arm choices in a T- maze (DEACON and RAWLINS 2006; 
RUBY et al. 2013). Mice were food restricted till they reached 80% of free-feeding weight 
after the completion of NOR test and then trained to run the DNMP task as described in 
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earlier studies with modifications (GOODLETT et al. 1988). The apparatus used was a 
wooden T-maze painted flat gray with a start arm and goal arms each 40 cm long and 12 
cm wide, with guillotine doors at the start arm and the entrance to each arm.  The maze 
was cleaned between each mouse by wiping the alleys with 70% ethanol. 
 
1. Phase 1- The mice were given three days of habituation and allowed to freely explore 
the T-maze and obtain chocolate milk at each arm.  
2. Phase 2- Mice were alley trained to run from the start arm to the end of a randomly 
selected goal arm with the other arm blocked off.  
3. Phase 3- Mice were then trained on the DNMP task to attain a criterion of 80% 
correct choices on three consecutive days.  Each day, they were given 8 “trial 
couplets”; the first trial of each couple was a “forced” run, in which one arm was 
blocked off and the entry was available to only one arm from the start arm.  After a 
10 second period to consume the milk, the mouse was placed back into the start area, 
both arms were opened and the milk was placed in the arm opposite from the 
previously arm, and the mouse was allowed to choose either of the two arms.  If the 
mouse chose the incorrect arm, it was allowed to move through the maze till it came 
to the correct arm and then was blocked in. After each trial couplet, the animal was 
returned to its home cage for 30 seconds. This training on “0 second” delay between 
the forced run and choice run of each trial couple continued daily until the mouse 
reached the 80% criterion on three consecutive days.  Half of the trials had the forced 
run to the left arm, while the other half was forced into the right arm, a schedule 
randomly assigned by the experimenter each day.   
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4. Phase 4- Once the mouse reached 80% criterion, an additional five days of testing 
ensued the next day, with each day having 8 “trial couplets” as described above with 
a 30 second delay between the forced and choice trial. During the 30 second delay, 
the animal was placed in a holding cup. After each trial couplet, the animal was 
returned to its home cage for 30 seconds. Delays were introduced to test spatial 
working memory function over delay intervals. 
 
2.2.5 Morris water maze (MWM) task 
The MWM is a hippocampal dependent learning and memory task which tests the 
ability of the mouse to use spatial cues to locate a hidden platform. The test consists of 7 
consecutive days of training, 4 trials per day, and followed 24 hours later by a probe test. 
The mice were trained in squads of 4 yielding a delay of 3-5 minutes between trials. The 
testing apparatus is a 9cm (diameter) platform that was placed in a 125cm (diameter) pool 
filled to within 25cm of the rim of the tank with 25°C water made opaque by adding non-
toxic white paint.  The top of the submerged platform was 0.5 cm below the surface of 
the water. The testing environment was illuminated and contained visual reference cues 
(e.g. posters, curtains). The platform position remained constant throughout training; 
however, the starting location of each series of 4 trials varied each training day.  The 
mice begin training in the water maze at 60 days of age, by an experimenter blind to 
treatment and genotype.  The computer-controlled tracking software displays the 
moment-to-moment position of the animal in the pool. Dependent variables assessed by 
this software included escape latency, escape path length, swim speed, initial heading 
angle and time spent in thigmotaxis (swimming the perimeter of the pool).  Training trials 
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consisted of placing the mouse in the pool (facing the rim of the tank) at one of 8 starting 
positions. The animal was allowed to swim for 60 seconds or until the platform was 
found. Different, pseudo-randomly determined, starting points were used for each trial. 
Animals were not started within the same quadrant as the target, nor were start positions 
repeated on a given day. If a mouse was unable to find the platform, it was guided to the 
platform by the experimenter. All animals remained on the platform for 10 seconds 
before being returned to their respective incubators (30°C), used to limit hypothermia 
during the waiting interval. Mice were tested in squads of 3 or 4, resulting in a waiting 
interval of approximately three minutes. At the end of each day of testing, the mice were 
allowed to remain in the incubators until warm and mostly dry (approximately 10 
minutes) before being returned to the vivarium. 
On the eighth day of training, animals were subjected to a single 60-second probe 
trial starting at a pseudo-randomly assigned location.  The platform was removed before 
the probe trial, and the animal’s search path was assessed via computerized video 
tracking superimposing four virtual counting discs over the pool in the location of each of 
the four possible platform positions used for the place training condition. The video 
tracking software (HVS Image, Hampton, UK) obtained measures of time spent in, 
latency to enter, and numbers of passes through each of the four virtual counting discs; 
these measures were used to quantify the spatial distribution of the search strategy of 
each animal. The escape platform location used during training was designated as the 
target counter and compared to the average of the non-target counter variables. 
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2.2.6 Statistical analysis  
Data for the locomotor activity was analyzed with a mixed ANOVA with 
Genotype and Treatment as grouping factors and Day and Bin as repeated measures.  The 
DNMP task and the NOR task were analyzed using two-way ANOVAs with Genotype 
and Treatment as grouping factors. The MWM acquisition data (average daily latency to 
find the platform) were analyzed with a mixed ANOVA with Genotype and Treatment as 
grouping factors and Day as the repeated measure.  For the probe day, time spent in the 
target quadrant virtual disk counter was analyzed with a two-way ANOVA. Significance 
was considered as p-values less than or equal to 0.05.  
 
2.2.7 Isolation of protein from brain tissue and quantification 
Total protein fraction of brain tissue was determined following a protocol adapted 
from previously published studies (PAPADOPOULOS et al. 2011; PONS-ESPINAL et al. 
2013). Tissue samples were isolated from brain segments (cortex, hippocampus and 
cerebellum) in RIPA buffer (10mM Phosphate Buffer (pH 7.4), 10% Glycerol (Fisher 
Scientific, Fair Lawn, NJ), 1% NP-40 (United States Biological, Swampscott, MA) 0.1% 
SDS (Fisher Scientific, Fair Lawn, NJ),  4mM EDTA (Fisher Scientific, Fair lawn, NJ), 
0.15M NaCl (Fisher Scientific, Fair Lawn, NJ), 1x Protease inhibitor cocktail (Roche 
Diagnostics, Mannheim, Germany) of a cohort of mice (trisomic and euploid) that were 6 
weeks of age. The tissue samples were snap frozen in liquid nitrogen and stored at -80°C 
until protein isolation. The isolated protein was quantified using a Bradford assay 
(BRADFORD 1976). The protein samples were stored at -80°C until further use.  
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2.2.8 Immunoprecipitation of Dyrk1a protein 
The protein sample was cleared of any antibodies by pre-incubation with EZ-view 
Red Protein affinity gel (30 µl, Sigma-Aldrich, St Louis, MO) for 30 minutes. The 
protein samples were then centrifuged at 16000g for 10 minutes at 4°C following which 
the supernatant was removed into fresh tubes. The lysate was mixed with 2 µl of mouse 
anti-Dyrk1a (7D10, Abnova, Taipei city, Taiwan) antibody, vortexed briefly and 
incubated for 1 hour at 4°C in a rotator. During incubation, Protein-G sepharose beads 
(4B, bioWORLD, Dublin, OH) were carefully mixed and dispensed (30 µl) into a fresh 
set of tubes placed on ice. The beads were gently washed by adding 500 µl of lysis buffer 
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% NP-40, 15% glycerol, 1 mM EDTA, and 
protease inhibitor (Roche Diagnostics, Mannheim, Germany) 1 tablet/50 mL added 
immediately before use and briefly vortexing the samples. The protein samples were then 
centrifuged for 30 seconds at 8200g. The supernatant was carefully removed and 
discarded and the beads were washed once more as described above. The tubes were 
placed on ice and the lysate-antibody mix was added into the beads. The tubes were 
briefly vortexed and incubated at 4°C overnight to facilitate the attachment of protein-
antibody complex on to the sepharose beads. Following the overnight incubation, the 
samples were centrifuged and placed on ice (1600g, 30 seconds, and 4°C). The 
supernatant was carefully removed and the beads were washed on ice as follows: 
 
1. 2 x in 500µl of wash buffer with NP-40 (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
2mM EDTA, 0.1% NP-40) 
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2. 2 x in 500µl of wash buffer without NP-40 (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
2mM EDTA) 
3. 1 x in 500µl of  kinase buffer (250 mM HEPES, pH 7.0, 50 mM MgCl2, 5 mM DTT) 
After the addition of each buffer, the tubes were vortexed briefly and gently mixed in a 
water bath (2-8°C) for 5 minutes. The samples were centrifuged (1600g, 30 seconds) and 
the supernatant was removed on ice. Following the removal of the kinase buffer, the 
beads were placed on ice and subjected to a kinase assay. 
 
2.2.9 Determination of kinase activity 
The kinase activity of the protein samples were determined using a previously 
published protocol adapted from Pons-Espinal, 2013 and personal communications with 
Prof. Dr. Walter Becker (PONS-ESPINAL et al. 2013; BECKER 2014). A master mix 
containing 1x kinase buffer, 100 µM ATP, and 200 µM Dyktide (Dyrktide-
RRRFRPASPLRGPPK, SignalChem, Richmond, BC) (HIMPEL et al. 2000) was prepared 
and 2 µCi/sample of [γ-32] ATP was added into the master mix immediately prior to use. 
Trisomic samples were incubated with 2µM Harmine (New Jersey, USA) and EGCG 
solutions of differing concentrations (10, 25, and 250 µM) to analyze the effect of 
inhibition on Dyrk1a kinase activity. The beads from the immunoprecipitation assay were 
incubated at 30°C for 50 minutes with 30 µl of master mix. Following incubation, the 
reaction was arrested by adding 1/3 volume 100 mM EDTA. 10 µl of each of the samples 
were blotted on to P81 Whatmann filter paper (GE Healthcare UK Limited, 
Buckinghamshire, UK) in triplicates and washed extensively (8 x 1mL of 5% phosphoric 
acid) under vacuum conditions. The filter papers were air dried and placed in plastic 
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scintillation vials and 5 mL of scintillation liquid (SX20-5 ScintiSafe Econo1 Cocktail, 
Fisher Chemical, Fair Lawn, NJ) was added into each vial. The vials were placed in the 
liquid scintillation counter (Beckman, LS 60001C) and the 32P levels were detected.  
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CHAPTER 3. RESULTS 
3.1 Effect of different EGCG supplements on correcting skeletal deficits in a Down 
syndrome mouse model 
 
3.1.1 HPLC analysis of EGCG supplements 
We hypothesized that EGCG supplements obtained from different sources would 
display differential effects in the amelioration of the skeletal phenotype, with EGCG 
resulting in the most significant benefits in Ts65Dn mice. To test our hypothesis, we 
performed HPLC analysis on the different EGCG supplements to identify the level of 
purity and composition. EGCG possessed a catechin content of >95% and exhibited a 
large peak on the HPLC-DAD1 (diode array detection) at a retention time of 2.5 minutes 
that was identified as EGCG and two small peaks at 1.5 and 1.7 minutes that were 
detected to be contaminants (Figure 3.1). EGCG displayed a relative abundance of m/z 
(mass/charge ratio) 459.0. TEAVIGO supplement had a manufacturer stated EGCG 
content of 90% of capsule weight and displayed the highest level of purity in comparison 
to EGCG with a retention time of 2.5 minutes and a single peak at m/z 459.0 that 
corresponded with EGCG (Figure 3.2). EGCgNOW DAD with a manufacturer stated 
catechin content of 50% by capsule weight showed three small peaks at 1.3, 1.9, and 4.4 
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minutes which corresponded with EGC, EC/EGCG, and ECG respectively and a larger 
peak at 2.6 minutes that corresponded with EGCG; with a m/z 459.0 (Figure 3.3). Based 
on the comparisons of purity obtained from HPLC, EGCgNOW was chosen as it 
appeared to have the least purity in comparison to the other compounds while TEAVIGO 
exhibited purity closest to that of EGCG and was chosen to compare the differential 
effects of EGCG compounds obtained from non-chemical companies.  
 
3.1.2 Degradation analysis of EGCG supplements by HPLC-MS 
The strong antioxidant nature of EGCG results in its rapid degradation and poor 
bioavailability (FERRUZZI et al. 2010). To study the rate of degradation and the effect of 
the addition of phosphoric acid to stabilize the catechin content, we conducted a 
degradation analysis of EGCG supplements by HPLC-MS. The EGCG solutions showed 
significant reduction in EGCG concentration following 24 and 48 hours incubation when 
compared to the 1 hour EGCG sample (Table 3.1).  LE EGCG had a significantly higher 
EGCG concentration than EGCG alone after 24 and 48 hour incubations while the 
addition of phosphoric acid to EGCG resulted in a significant increase in EGCG 
concentrations at 24 and 48 hours when compared to the same time points of EGCG only 
samples. DE EGCG had a significantly lower EGCG concentration following 1 hour of 
incubation but after 24 and 48 hours, DE EGCG showed a significantly higher EGCG 
concentration than EGCG at same time points (Table 3.1). TEAVIGO and EGCgNOW 
supplements behaved the poorest with both supplements resulting in significantly reduced 
EGCG concentrations following 1, 24, and 48 hours of incubation in comparison to 
EGCG samples at the same time points (Figure 3.4).  
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3.1.3 Dual energy X-ray absorptiometry (DXA) 
To compare the density of the femurs and skulls between mice treated with the 
different EGCG supplements, DXA analysis was performed following the removal of the 
bones at 6 weeks. Bone mineral density (BMD), bone mineral content (BMC) and area 
data were obtained from DXA scanning and analyzed to study the effect of each 
treatment. BMD of trisomic femurs treated with water (control) were compared to 
euploid control mice to establish a genotype effect and we observed a significant 
reduction in BMD of trisomic femurs. The treatment of trisomic mice with EGCG 
resulted in a significant increase in BMD compared to control trisomic mice (Figure 3.5). 
However, the increase in BMD imparted by TEAVIGO and EGCgNOW treatment in 
trisomic mice was non-significantly less than that of EGCG treated trisomic mice. DXA 
analysis of skulls of EGCG treated trisomic mice showed that EGCG, TEAVIGO, and 
EGCgNOW treatments led to no significant improvements in BMD (Figure 3.6). 
 
3.1.4 Micro CT imaging and analyses 
Micro CT imaging was utilized to study the microstructure and organization of 
the trabecular bone (distal end) and cortical bone (mid shaft) of femurs. Results from our 
study agreed with the observations of a previous study conducted in our lab by showing 
that trisomic mice have a greater trabecular separation, reduced percent bone volume 
(BV/TV), trabecular number and thickness (BLAZEK 2011). We observed that EGCG 
treatment lead to a significant increase in percent bone volume and trabecular thickness 
to control trisomic mice. TEAVIGO supplement significantly reduced trabecular 
separation in trisomic mice compared to EGCG treated Ts65Dn mice; while EGCgNOW 
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resulted in a significant increase in percent bone volume and trabecular number in 
Ts65Dn mice when compared to EGCG treated trisomic mice (Table 3.2). 
Blazek et al.,  identified significant reductions in bone perimeter and mean polar 
moment of inertia in trisomic cortical bone  in comparison to euploid controls (BLAZEK 
2011). In our study we observed a similar result with trisomic femurs without treatment 
showing a significant reduction in bone perimeter and polar moment of inertia (Table 3.3). 
Treatment of trisomic mice with EGCG resulted in no significant improvement in bone 
perimeter or polar moment inertia compared to euploid control mice while TEAVIGO 
and EGCgNOW treatment lead to significant improvements in both cortical bone 
parameters when compared to EGCG treated trisomic bones (Table 3.3).   
 
3.1.5 Mechanical Testing 
To determine the effect of structural changes observed by micro CT and DXA on 
the bone strength, a three-point bend test was performed on both euploid and trisomic 
femurs. In a previous study by Blazek and colleagues, it was shown that Ts65Dn femurs 
had a significantly lower ultimate force (the maximum force that is sustained by the 
bone), stiffness (area under load-deformation curve before bone is broken) and energy to 
failure (area under load-deformation curve before bone is broken) than euploid mice 
(BLAZEK 2011). Our study replicated the results from the Blazek study and showed 
significant reductions in ultimate force, stiffness, and energy to failure of trisomic control 
femurs when compared to euploid controls. We observed that EGCG treatment led to a 
significant improvement in the energy to failure of trisomic femurs compared to trisomic 
water treated mice (Figures 3.7, and 3.8). TEAVIGO and EGCgNOW treatment of 
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trisomic mice only resulted in significant reduction in all three mechanical test 
parameters in comparison to EGCG treated Ts65Dn mice (Figures 3.7, 3.8 and 3.9). 
Furthermore, we observed that TEAVIGO and EGCgNOW supplements significantly 
reduced all euploid bone measures while pure EGCG significantly lowered the energy to 
failure compared to euploid control mice.  
 
3.2 Study the effect of a 3 week EGCG treatment on the learning and memory defects 
in the Ts65Dn mouse model of Down syndrome 
 
3.2.1 Locomotor activity 
The locomotor activity task was utilized to analyze the spontaneous activity 
patterns of trisomic mice in comparison to controls. Several studies have reported that 
trisomic mice display a significantly higher level of spontaneous activity in comparison 
to wild type mice (HOLTZMAN et al. 1996; SAGO et al. 2000). Figure 3.10A shows 
locomotor activity as a function of distance traveled per 1-minute bins on each of the two 
days of testing.  There was a significant effect of Genotype [F(1,67)=7.28, p=0.009], but 
no significant effect of EGCG treatment.  The effect of genotype was due to the higher 
daily locomotor activity of the trisomic mice compared to the euploid mice, as shown in 
Fig. 3.10B.   
 
3.2.2 Novel object recognition (NOR) 
Rodents have a natural preference to explore novel objects over familiar objects.  
In the NOR task, testing preference for a novel object over one that has been recently 
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encountered, can be utilized to study the object recognition memory, and trisomic mice 
have been found to be impaired relative to euploid controls (FERNANDEZ et al. 2007; 
SMITH et al. 2014). The discrimination ratios from the Novel Objet Recognition data 
were analyzed with a two way ANOVA using Genotype and Treatment as a between 
subjects variable.  A significant effect of genotype was found [F(1,63)=4.289, p=0.042], 
due to the lower discrimination ratios of the Ts65Dn mice (see Fig.3.11); there was no 
significant main or interactive effect of EGCG treatment on NOR.  
 
3.2.3 Delayed non-matching to place (DNMP) task 
The DNMP task was utilized to analyze acquisition of a spatial working memory 
task.. A two-way ANOVA was used to examine the number of trials to criterion (number 
of trials required by the mouse to reach 80% correct choices on three consecutive days in 
the “0-sec delay” training) in Ts65Dn mice. A significant effect of genotype was found 
[F(1,21)=6.56, p=0.018] indicating that trisomic mice required more trials to learn the 
task (Figure 3.12). However, there were no significant main or interactive effects of the 
three week EGCG treatment on DNMP acquisition. 
 
3.2.4 Morris water maze (MWM) task 
The MWM spatial learning task is a commonly utilized test to study hippocampus 
dependent spatial learning and memory behaviors (MORRIS et al. 1982). Multiple studies 
have reported significant deficits in trisomic mice in both the latency (time taken to reach 
the platform) and spatial search strategies in probe trials in comparison to control mice 
(REEVES et al. 1995; SAGO et al. 2000; HYDE et al. 2001). The average daily latency over 
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the seven days of training was analyzed using a mixed ANOVA with day as repeated 
measure.  There was a significant main effect of Genotype [F(1,20)=6.96, p=0.016], in 
addition to the significant main effect of day [F(6,120) = 11.008, p<.001] (Figure 3.13). 
 For the probe trial, the trial time spent in the virtual target disc (in the target 
quadrant) and the average time spent in the 3 equivalent virtual non-target discs (in the 
other 3 quadrants) were analyzed using a mixed ANOVA with treatment group and 
genotype as between-group factors and disc location (target vs non-target) as a repeated 
measure. There was a significant effect of disc location [F(1,20)=12.586, p=0.002] 
(Figure 3.14); the lower target search times of the trisomic mice did not reach statistical 
significance (p=0.054).  The EGCG treatment did not significantly affect either the 
acquisition latency measures or the time spent in target quadrant during probe day. 
 
3.2.5 Dyrk1a kinase assay 
The triplication of Dyrk1a gene dosage and the resulting increase in protein 
kinase activity levels have been hypothesized to be a major cause of the cognitive 
phenotype observed in individuals with DS and Ts65Dn mice (KORENBERG et al. 1994; 
ARRON et al. 2006). In previous studies, the kinase activity in the brains of trisomic mice 
was shown to have a 1.5 fold increase in activity than in the euploid samples (GUIMERA 
et al. 1999; DOWJAT et al. 2007). In our study the Dyrk1a kinase activity of trisomic 
hippocampal tissue showed a ~ 1.6 fold increase compared to a euploid tissue (Figure 
3.15). The addition of Harmine, a chemical inhibitor of Dyrk1a kinase activity resulted in 
a ~0.7 fold reduction (BECKER 2014). Furthermore, we observed a dose-dependent 
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reduction in Dyrk1a kinase activity of 1.2, 0.9, and 0.8 fold with the addition of 10, 25, 
and 250 µM of EGCG to trisomic hippocampal tissue samples respectively.   
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CHAPTER 4. DISCUSSION 
4.1 Different composition of EGCG supplements results in differential effect in the 
rescue of skeletal phenotype in Ts65Dn mice 
Our study demonstrates that (1) EGCG supplements improved cortical bone and 
some trabecular bone measures with no concurrent improvement in bone mechanical 
properties in Ts65Dn mice, (2) EGCgNOW and TEAVIGO undergo rapid degradation 
under room temperature conditions resulting in poor bioavailability of EGCG polyphenol.  
Previous studies have shown that individuals with DS have a significantly reduced areal 
BMD in the femoral neck, spine, hip, total body, total hip, and lumbar spine in 
comparison to healthy individuals (BAPTISTA et al. 2005; GUIJARRO et al. 2008). 
Therefore, it was hypothesized that Trisomy 21 may result in several risk factors that 
predispose individuals with DS to an osteoporosis like phenotype (GUIJARRO et al. 2008). 
The skeletal deficits observed in humans with DS have been shown to be present in the 
Ts65Dn mouse model as well. In a previous study conducted in our lab, Blazek et al. 
identified significant reductions in BMD of femurs, percent bone volume (BV/TV), 
trabecular thickness, number, mineral apposition  rate, bone formation rate, and bone 
strength in adolescent and adult Ts65Dn mice (BLAZEK 2011). The adolescent skeletal 
deficits together with changes in serum bone markers were also present in adult mice (3 
& 24 month) (FOWLER et al. 2012). In our study we observed significant reduction of 
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BMD, percent bone volume, trabecular number, thickness, and bone strength properties 
together with an increase in trabecular separation in trisomic mice compared to euploid 
littermates. Epigallocatechin-3-gallate (EGCG), the main polyphenolic compound in 
green tea was chosen as a therapeutic target as it is a selective inhibitor of Dyrk1a activity 
and in Fetal Alcohol Syndrome (FAS) studies it has been shown to ameliorate 
craniofacial and cognitive phenotypes. (BAIN et al. 2003; ADAYEV et al. 2006; LONG et al. 
2010; TIWARI et al. 2010). FAS and DS share many phenotypic similarities and it is 
therefore believed that they share some common mechanisms at the cellular and 
molecular levels (SOLZAK et al. 2013). Analysis of femurs following EGCG treatment by 
Blazek et al. showed significant improvement of femoral BMD, percent bone volume, 
trabecular thickness, and trabecular number compared to euploid littermates. They further 
observed an increase in mineral apposition rate in Ts65Dn femurs with no positive effects 
on the energy to failure, stiffness, and ultimate load on the trisomic femurs (BLAZEK).  
In our current study, we analyzed the effect of over the counter EGCG 
supplements on the femurs of Ts65Dn mice. We observed a significant increase in 
percent bone volume and trabecular number with EGCgNOW supplement and a 
significant increase in cortical bone measures with both supplement treatments. HPLC 
analysis of EGCgNOW revealed the presence of EGC and ECG, the 2nd and 3rd most 
common green tea catechin after EGCG (KHOKHAR et al. 1997). EGCG and ECG are the 
most active green tea catechins with a multitude of biological actions (HAE-SUK KIM 
2014). EGC treatment of rat osteoblast-like osteosarcoma cell line have shown that this 
green tea catechin can promote osteoblast activity while inhibiting osteoclast 
differentiation in RAW 267.7 cell lines (KO et al. 2009). The strong anti-oxidant nature 
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of EGCG, ECG, and EGC results in their rapid degradation at near-neutral and high pH 
conditions (QIN YAN ZHU 1997; CHEN et al. 2001). Catechins also undergo extensive 
degradation under digestive conditions (NEILSON et al. 2007). Digestion of EGCG in an 
in-vitro digestion model was shown to result in a digesta containing residual EGCG, 
EGCG C2ʹ- C2ʹ homodimers THSN A, THSN D, and EGCG B-ring condensation-
elimination homodimer P-2 (NEILSON et al. 2007). The EGC digesta contained residual 
EGC, gallocatechin (GC), and EGC homodimers similar to those observed for EGCG and 
ECG digesta contained residual ECG and catechin gallate (CG) (NEILSON et al. 2007). 
Therefore, we hypothesize that the presence of other catechins in supplements, 
degradation of EGCG, ECG, and EGC from exposure to light and room temperature (RT), 
and intestinal digestion may play a crucial role in the differential skeletal effects observed 
with EGCG supplements. The analyses of EGCG preparations following 1, 24, and 48 
hour incubations by HPLC indicate that pure EGCG and in particular the supplements 
underwent rapid degradation over time, resulting in very low levels of EGCG at the end 
of 48 hours of exposure to RT conditions.   
We observed that EGCG supplements, in particular EGCgNOW led to an increase 
of trabecular thickness, trabecular number, percent bone volume, bone perimeter, and 
polar moment of inertia compared to euploid controls. However, it did not result in an 
improvement in mechanical strength of the femur. We hypothesize that the improvements 
in trabecular and cortical bone measures by EGCG supplements does not affect the actual 
toughness of the bone. Toughness is a measure of resistance to fracture formation and 
collagen fiber play an integral role in this function (R.K. NALLA 2006; RITCHIE et al. 
2008). In a normal individual collagen fibrils undergo deformation and elongation under 
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force but return to normal with the removal of the force (RITCHIE et al. 2008). However, 
in aged collagen a higher number of cross-links are formed which results in a “brittle” 
bone which is more susceptible to fractures. R.K. Nalla et al. demonstrated that fracture 
toughness of cortical bone is significantly reduced in aged individuals (R.K. NALLA 
2006). Individuals with DS undergo accelerated aging and therefore are afflicted with age 
related diseases such as osteoporosis like bone phenotype. The supplements, EGCg NOW 
and TEAVIGO may increase cortical and trabecular measures without affecting the 
collagen structure and therefore we observe no improvements in mechanical strength 
properties of the bone.  EGCgNOW and TEAVIGO were observed to significantly 
decrease stiffness, ultimate force, and energy to failure for euploid mice which indicates 
that these supplements alter the mechanical properties of bone.  The supplements may be 
harmful in the absence of overexpression of Dyrk1a and therefore could be harmful if 
used by a normal individual. Therefore, further studies need to be performed to analyze 
the effect of EGCG supplements in the absence of trisomy before it can be used to rescue 
bone deficits in normal individuals.  
 
4.2 Three week treatment of adolescent Ts65Dn mice with low dose EGCG resulted in 
no improvement of learning and memory deficits. 
All individuals with DS are affected by learning and memory deficits which occur 
early and persist throughout life (EPSTEIN 2001b; GARDINER et al. 2003). Ts65Dn mice 
recapitulate the DS cognitive phenotype and therefore provide an excellent predictive 
organism to study the effect of trisomy on learning and memory functions (ESCORIHUELA 
et al. 1995; REEVES et al. 1995). Our results showed that trisomic mice are significantly 
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more active, require a significantly higher number of trials to reach criteria in the DNMP 
task, have a significant lower discrimination ratio in NOR, and have a significantly 
higher latency in training phase of the Morris water maze. The results from our study 
support observations from previous studies and show that Ts65Dn mice are affected with 
learning and memory deficits that center around the hippocampus (REEVES et al. 1995; 
HYDE et al. 2001; FERNANDEZ et al. 2007; KLESCHEVNIKOV et al. 2012).  
However, we did not observe a rescue effect in trisomic mice treated with a low-
dose EGCG during adolescence in the behavioral tasks performed. In a recently 
published study, treatment of adult Ts65Dn with a EGCG supplement was shown to 
improve spatial learning in MWM and object recognition in NOR (DE LA TORRE et al. 
2014). Two distinct differences exist between our study and De La Torre et al.: (1) we 
treated adolescent mice (aged 3-6 weeks) while De La Torre study used adult (3 months) 
mice and, (2) we treated mice with 0.124 mg/ mL (0.6-0.7 mg/day) for three weeks while 
the De La Torre study treated their animals at a concentration of 90 mg/mL (2-3 mg/day) 
for 1 month.   
EGCG is a selective inhibitor of Dyrk1 protein activity and undergoes rapid 
degradation following administration (BAIN et al. 2003; FERRUZZI et al. 2010). The 
plasma levels of EGCG following oral gavage were shown to return to baseline levels in 
as short as 6 hours in rats (FERRUZZI et al. 2010). Therefore, we hypothesize that the 
short duration of treatment of adolescent mice with a low concentration of EGCG may be 
insufficient to improve hippocampal dependent learning and memory deficits.  
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4.3 Future directions 
Our studies revealed that ready available EGCG supplements result in 
confounding effects. We observed that supplements can improve trabecular and cortical 
bone measures but with no concurrent improvement in mechanical strength. Furthermore, 
HPLC analysis of the supplements showed the presence of other green tea catechins and 
rapid degradation in solution. We observed a significant reduction in energy to failure, 
stiffness, and ultimate force in euploid mice treated with TEAVIGO and EGCgNOW for 
three week during adolescence. The popularity of EGCG in DS research and wide interest 
in these published studies from the DS community suggests we as researchers need to be 
very careful in reporting results from our studies. Therefore, we propose that more 
studies into the safety of EGCG herbal supplements to normal as well individuals with 
DS need to be performed before EGCG can be recommended for human use. The rapid 
degradation under neutral/ basic conditions should be addressed by creating a better 
transport mechanism for EGCG. EGCG that can be specifically targeted to a particular 
region of the body will be more effective than a general capsule approach. In another step 
to elucidate the Dyrk1a-Nfat mechanism, we would begin treatment of three week old 
Ts65Dn and control mice with an Nfatc inhibitor, cyclosporin A. We hypothesize that if 
skeletal defects are a  result of Dyrk1a- Nfatc  pathways as proposed, we will observe 
reduced BMD, altered trabecular, cortical bone structures, and mechanical properties of 
bone  in euploid and trisomic mice. Previous studies conducted in our lab indicate that the 
trisomic skeletal deficit is a result of an increase in osteoclasts and therefore increased 
resorption of bone. In-vitro cell culture of osteoclast cells from euploid and trisomic bone 
marrow cells will provide us with a convenient method to study the role of trisomy on 
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osteoclast development. The application of EGCG from chemical as well as over the 
counter sources will help us further analyze the effect of supplements on bone 
development. 
We observed no EGCG effect on the behavioral phenotype of Ts65Dn mice when 
treatment was performed during adolescence.  We propose moving forward; treatment is 
continued throughout the behavioral testing period. As EGCG is a selective Dyrk1a 
kinase inhibitor, it should be present continuously in order to observe improvements in 
the cognitive defects. The pH of the EGCG treatment should be lowered to more acidic 
levels (5-5.5) by the addition of phosphoric acid to reduce the rate of degradation that 
was observed in HPLC-MS analysis. This will produce a more uniform concentration of 
EGCG during the treatment period and reduce concentration related fluctuations in data. 
Dyrk1a knock-out mice, with the normal trisomic complement of genes except for 
Dyrk1a (reduced to two copies) should be incorporated into behavioral studies to observe 
the role of Dyrk1a in hippocampal dependent learning and memory deficits. Furthermore, 
we propose that Dyrk1a kinase activity of protein isolated from the hippocampal tissue of 
EGCG treated mice following the end of behavioral testing be analyzed to study the 
effect of continuous EGCG treatment on kinase activity. Finally, a study of the different 
green tea catechins (ECG, EGC, and EC) both as a pilot mouse study and kinase activity 
study should be performed to analyze the effect of these catechins on both skeletal and 
behavioral phenotype in the Ts65Dn mouse model. 
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TABLE 
 
2.1: Percentage of EGCG in different supplements.  
The amount of EGCG present in the treatments utilized to study the effect of EGCG on 
the skeletal phenotype in Ts65Dn mouse model. 
 
Name Source Weight of capsule % of EGCG/capsule 
EGCG Sigma-Aldrich  >95%  
EGCgNOW NOW FOODS 400mg 50% (200mg) 
TEAVIGO Healthy Origins 150mg 90% (135mg) 
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3.1: Degradation analysis of EGCG supplements by HPLC-MS. 
Results showed that LE EGCG showed the most stability over time and that the addition 
of phosphoric acid results in the increase of EGCG stability while TEAVIGO and 
EGCgNOW were the most unstable, resulting in significant reduction in EGCG 
concentration over time.   
 
Treatment Time point Expected 
concentration 
(mg/mL) 
Calculated 
concentration 
(mg/mL) 
EGCG (3) 1 1 1.001±0.0015 
 24 1 0.3349±0.014A 
 48 1 0.1699±0.013A 
EGCG+Phosphoric acid 
(3) 
1 1 0.9833±0.008 
 24 1 0.5068±0.003B 
 48 1 0.4637±0.0013C 
Lightly caffeinated 
EGCG- LE EGCG (3) 
1 1 1.0567±0.01D 
 24 1 0.6038±0.012B 
 48 1 0.3975±0.05F 
Decaffeinated EGCG- 
 DE EGCG (3) 
1 1 0.9294±0.006A 
 24 1 0.5624±0.017B 
 48 1 0.3083±0.011C 
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3.1, continued. 
 
 
TEAVIGO (3) 1 1 0.5376±0.0009A 
 24 1 0.1247±0.005B 
 48 1 0.0601±0.002C 
EGCgNOW (3) 1 1 0.3918±0.004A 
 24 1 0.1115±0.0005B 
 48 1 0.0823±0.0004E 
A p< 0.001 when compared to 1 hour EGCG; B p< 0.001 compared to 24 hour EGCG;       
C p≤0.001 compared to 48 hour EGCG; D ≤0.05 compared to 1 hour EGCG; E ≤0.05 
compared to 48 hour EGCG; F≤0.01 compared to 48 hour EGCG 
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3.2: Trabecular bone analysis by micro CT. 
We observed significant alteration of trabecular bone structure in trisomic mice compared 
to euploid controls. EGCG improved the percent bone volume and trabecular number of 
trisomic mice in comparison to untreated Ts65Dn mice. EGCgNOW treatment resulted in 
improvement of percent bone volume and trabecular number while only the TEAVIGO 
treatment could significantly improve trabecular separation when compared to EGCG 
treated trisomic mice.   
 
Genotype Treatment Percent bone 
volume 
(BV/TV) 
Trabecular 
separation 
(mm) 
Trabecular 
thickness 
(mm) 
Trabecular 
number 
(mm-1) 
Euploid Water 16.3±1.02  0.25±0.009 0.053±0.001 3.04±0.2 
 EGCG 15.3±0.62 0.27±0.008 0.053±0.001 2.85±0.1 
 TEAVIGO 17.1±1.0 0.25±0.01 0.057±0.002 3.0±0.15 
 EGCgNOW 18.0±1.44 0.27±0.008 0.06±0.002 3.2±0.2 
Trisomic Water 9.1±1.1A,B 0.30±0.015C 0.05±0.001C 1.86±0.21A 
 EGCG 12.5±1.04D 0.27±0.007 0.053±0.001 2.35±0.16D 
 TEAVIGO 13.8±1.4 0.30±0.012B 0.057±0.002 2.13±0.12 
 EGCgNOW 15.0±0.95B 0.27±0.013 0.06±0.002 2.73±0.12B 
A p≤0.001 compared to euploid water; B p≤0.05 compared to trisomic EGCG; C p<0.05 
compared to euploid water; D p<0.05 compared trisomic water. 
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3.3: Cortical bone analysis by micro CT. 
The bone perimeter and the polar moment of inertia were significantly reduced in 
trisomic control mice compared to euploid controls. EGCgNOW and TEAVIGO 
treatment resulted in significant improvement in both cortical bone parameters in trisomic 
mice compared to trisomic controls.  
 
Genotype Treatment  Bone perimeter Polar moment of inertia 
Euploid Water 13.43±1.13 0.47±0.04 
 EGCG 12.1±0.66 0.47±0.042 
 TEAVIGO 16.41±1.91 0.49±0.05 
 EGCgNOW 18.9±2.02 0.57±0.04 
Trisomic Water 9.14±0.23A 0.27±0.022A 
 EGCG 8.88±0.18 0.27±0.021 
 TEAVIGO 14.2±1.07B 0.43±0.03B 
 EGCgNOW 14.9±1.92C 0.42±0.05C 
A <0.05 compared to euploid water; B <0.001 compared to trisomic EGCG;  
C <0.05 compared to trisomic EGCG 
 
 
 
  
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURES 
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FIGURES 
 
 
 
 
Figure 1.1 Gene orthologs of human chromosome 21 (Hsa21) found on three mouse 
chromosome, Mmu10, 16, and 17. 
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Figure 1.2: Dyrk1a-NFATc1 pathway.  
Entry of Ca2+ ions into the cytoplasm activates calcineurin. Activated calcineurin 
dephosphorylates Nfatc1, moving it from the cytoplasm into the nucleus. Nuclear Dyrk1a 
phosphorylates Nfatc and thus removes it to the cytoplasm.  
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Figure 1.3: Chemical structures of green tea catechins 
 
(-)-Epicatechin-3-gallate (ECG) 
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73 
 
 
 
 
Figure 3.1: HPLC analysis of EGCG 
Analysis of sigma EGCG by HPLC revealed a large peak at 2.6 minutes which was 
identified as EGCG while the two smaller peaks were contaminants. 
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Figure 3.2: HPLC analysis of TEAVIGO 
TEAVIGO supplement showed a large peak at 2.6 minutes, identified as EGCG. No other 
catechins were detected by HPLC and TEAVIGO was chosen for animal treatment as it 
was the closest to sigma EGCG in purity. 
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Figure 3.3: HPLC analysis of EGCgNOW 
EGCgNOW had the highest level of impurities with small peaks at 1.4, 1.9, and 4.4 
minutes that corresponds with EGC, EC/EGCG, and ECG respectively. The large peak at 
2.6 minutes was identified as EGCG. EGCgNOW was chosen for animal treatment to 
study the differential effects of the supplements. 
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Figure 3.4: Degradation analysis of EGCG supplements by HPLC-MS 
Analysis was conducted using HPLC/MS to find the EGCG concentrations at 1, 24 
and 48 hours after the preparation. These results showed that lightly caffinated EGCG 
(LE EGCG) and decaffinated EGCG (DE EGCG) were the most stable. EGCG 
underwent rapid degradation by 24 and 48 hours but the addition of phosphoric acid 
(H3PO4) resulted in the stabilization of EGCG concentration. Number within parenthesis 
indicates the number of replicates used in the study. 
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Figure 3.5: BMD analysis of femurs of Ts65Dn and control mice 
BMD of femurs were calculated using DXA analysis and results indicated a significant 
reduction in BMD in trisomic mice treated with water in comparison to euploid control 
mice (*, p<0.001). Treatment o of trisomic mice with EGCG resulted in a significant 
increase in BMD when compared to trisomic water treated mice (**, p=0.05).  
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Figure 3.6: DXA analysis of skulls of Ts65Dn and control mice 
BMD of the skulls revealed no significant changes with any of the three EGCG 
preparations used in this study. 
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Figure 3.7: Mechanical test analysis of ultimate force 
The maximum force that is sustained by the femur is referred to as ultimate force. The  
results showed that trisomic femurs could bear a significantly lower force than euploid  
control femurs (*, p=<0.001). None of the EGCG treatments were successful at 
increasing the ultimate force that could be borne by trisomic femurs. 
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Figure 3.8: Energy to failure analysis of femurs by mechanical test 
The energy to failure is described as the area under the load-deformation curve of a bone  
before it is broken. Trisomic control mice had a significantly lower energy to failure than 
euploid controls (*, p=≤0.005). The treatment of trisomic mice with EGCG resulted in a 
significant increase in energy to failure of the femurs in comparison to trisomic mice 
treated with water (**, p=0.05).  
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Figure 3.9: Mechanical test analysis of stiffness  
The stiffness of a bone is described as the linear portion of the load-deformation curve. 
We observed a significant reduction in stiffness of trisomic mice compared to euploid 
control mice (*, p=0.03), but no significant effect of EGCG supplement was observed. 
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Figure 3.10: Locomotor activity 
Activity task was utilized to study the spontaneous activity profile of trisomic mice  
in comparison to euploid controls and the effect of a three week long EGCG treatment of  
their activity levels. Trisomic control mice showed a significant increase in activity levels  
compared to euploid mice (3.10A, p=0.009). We did not observe an EGCG treatment 
effect. Effect of genotype in day 1 and 2 are shown in 3.10B.  
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Figure 3.11: Novel object recognition task 
The results from the study showed significant reduction in the discrimination ratio  
(the ratio of time spent exploring the novel object over familiar object) in trisomic mice 
in comparison to euploid animals (p=0.042). A three week EGCG treatment 
resulted in no improvements in the discrimination ratio in trisomic mice compared to 
euploid controls.  
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Figure 3.12: Delayed non-matching to place task 
DNMP results showed a significant increase in the number of trials required by 
trisomic mice to make 80% correct arm choices on three consecutive days in 
comparison to euploid mice (p=0.018). However, EGCG treatment did not rescue 
this deficit.  
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Figure 3.13: Morris water maze training latency 
The mice were trained for 7 consecutive days to swim to a hidden platform placed in a 
previously designated quadrant of the pool. We observed a significant genotype effect 
(p=0.016) with trisomic mice requiring a longer time than euploid mice to find the 
platform. However, no treatment effect was observed.  
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Figure 3.14: Morris water maze probe day 
Probe day is utilized to test the ability of the animals to use their training to find the  
quadrant where the platform was previously hidden. We observed a strong but  
nonsignificant trend towards a genotype affect in the time spent swimming in/through the 
target quadrant by trisomic control mice. However no EGCG treatment effect was 
observed in the trisomic mice in comparison to euploid controls. 
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Figure 3.15: Dyrk1a kinase activity assay 
Hippocampal tissue samples were analyzed using a 32P kinase assay. We observed a 
approximate 1.6 fold increase in kinase activity in the trisomic sample in comparison to 
euploid control samples. The addition of harmine (2µM) to the trisomic sample led to a 
0.7 fold reduction in kinase activity. A dose-dependent reduction in kinase activity was 
observed with the addition of 10, 25, and 250 µM EGCG solutions to trisomic 
hippocampal tissue samples.  
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